Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone furoate nasal spray for uncomplicated acute rhinosinusitis
NL-OMON35004Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluticasone in acute rhinosinusitis (ARS) (3 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in daily major symptom score over the entire treatment period. Started Feb 2010; status: active, not recruiting.
02
Drugs
fluticasone
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on NL-OMON35004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35004.